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documented evidence about the use 
of the speciﬁ  c milk replacers, we con-
servatively assumed that 12 of 13 case 
farms used the speciﬁ  c milk replacers. 
We estimated the odds ratio for this 
risk factor by using logistic regression 
analysis. Our results indicated that the 
use of the milk replacers produced by 
the speciﬁ   c factory was associated 
with BSE infection (odds ratio [OR] 
39.3, 95% conﬁ   dence interval [CI] 
4.9–312.9, p = 0.0005). 
The milk replacers produced by 
the speciﬁ  c factory contained tallow 
that was produced at domestic render-
ing factories and imported from the 
Netherlands. Milk replacers were fed 
to calves during a relatively short pe-
riod after birth (an average of 79 and 
68 days, for case and control farms, 
respectively). If 1 production lot of 
milk replacer became accidentally 
contaminated with BSE, the exposure 
would occur in newborn calves within 
a relatively short period. This con-
tamination may explain why 11 of 13 
BSE-infected calves were born within 
a 2-month period from February 10, 
1996, to April 8, 1996. 
In Hokkaido, 9 of 10 BSE-infect-
ed calves were fed calf concentrates 
produced in the same feed factory. 
This proportion was higher than that 
of the 50 control farms in Hokkaido 
(22/50, Fisher exact test, p = 0.013). 
The calf concentrates might have be-
come contaminated with meat-and-
bone meal (MBM) because this fac-
tory used MBM for other animal feed. 
Multivariate logistic regression analy-
sis, including this factor and that for 
the speciﬁ  c milk replacers, did not in-
dicate signiﬁ  cant association between 
the speciﬁ  c calf concentrates and oc-
currence of BSE (calf concentrates: 
OR 3.2 [CI 0.8–13.0], p = 0.14; milk 
replacers: OR 21.7 [CI 2.5–192.6], 
p = 0.006). The factory that provided 
the speciﬁ  c concentrates belonged to 
a company afﬁ   liated with the com-
pany that produced the milk replacers 
in question. Given the fact that farm-
ers tend to use milk replacers and calf 
concentrates from the same company, 
association of the calf concentrates 
with the BSE infection may have been 
masked by the use of speciﬁ  c milk re-
placers. However, our study is limited 
by the small number of BSE cases and 
investigation of events that occurred 
10 years ago.   
A possible causal association be-
tween the feeding of potentially con-
taminated milk replacers to calves and 
the occurrence of BSE has been sug-
gested by several epidemiologic stud-
ies (2–5). However, no report shows 
experimental transmission of BSE by 
use of tallow or milk replacers (6). 
This lack of evidence in the literature 
may suggest that the risk of contract-
ing BSE from processed tallow or 
milk replacers is low (7). If MBM is 
excluded as a source of infection, oth-
er transmission mechanisms, such as 
the feeding of animal fat, may become 
more important. 
This research was conducted under 
a research project for using advanced 
technologies in agriculture, forestry, and 
ﬁ  sheries.  
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Control of Hepatitis 
A by Universal 
Vaccination of 
Adolescents, 
Puglia, Italy 
To the Editor: The incidence of 
hepatitis A in Italy has decreased in the 
past 2 decades because of improved 
sanitation and better living conditions 
(1). However, large outbreaks oc-
curred in the 1990s in several southern 
regions of Italy, despite lower rates of 
infection among the general popula-
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tion (2–4). Person-to-person transmis-
sion has been recognized as a major 
factor in spread of this disease during 
this period (5).
Safe and highly effective hepatitis 
A vaccines have been available since 
1995. Nevertheless, their use has been 
limited to the Western Hemisphere. 
Universal vaccination programs have 
been initiated only in the United States 
and Israel before 1998 (6). In 1998, af-
ter a large epidemic of hepatitis A, a 
vaccination program for toddlers and 
adolescents was initiated in Puglia in 
southeastern Italy, which has a popu-
lation >4 million. This vaccine was of-
fered free to all children 15–18 months 
of age and to adolescents 12 years of 
age. Until 2002, a combined hepatitis 
A plus B vaccine had been used for 
vaccination of adolescents as part of 
the national hepatitis B immunization 
program. In 2003, this hepatitis B vac-
cination program ended; only hepati-
tis A vaccines containing 1 antigen are 
now used. No catch-up vaccination 
campaign has been planned. 
We analyzed disease surveil-
lance and vaccine coverage data for 
1991–2006 to evaluate the effect of 
such a vaccination program on hepa-
titis A incidence in persons in Puglia 
during the 9 years after initiation of 
the program. In the period before the 
vaccination program was initiated 
(1989–1997), annual incidence rates 
of hepatitis A in Puglia ranged from 
4.3 to 139.8 cases/100,000. The av-
erage annual rate during this period 
was 49.5 cases/100,000. Two large 
outbreaks were reported in Puglia, 
the  ﬁ   rst in 1992 and the second in 
1996–1997 (5). During the 9 years 
after start of the vaccination program 
(1998–2006), incidence of hepatitis 
A decreased from 22.8 cases/100,000 
in 1998 to 0.7 cases/100,000 in 2006 
(Figure). In the same period in other 
regions of Italy, incidence of hepatitis 
A was 5 cases/100,000, without any 
evident annual peak.
Since 2002, annual incidence 
rates in Puglia have remained at <2.8 
cases/100,000, lower than those in the 
rest of Italy. This incidence has been 
observed in all age groups, without 
any differences between vaccinated 
and unvaccinated birth cohorts. Vac-
cination coverage among children 
15–18 months of age was <20% dur-
ing the period of the vaccination pro-
gram. Coverage levels in adolescents 
reached 65% in the third year after the 
start of the program and then ranged 
from 57% to 72% (Figure).
Hepatitis A has been a serious 
public health problem in Puglia. This 
disease has had a detrimental effect 
on the local economy, which is based 
on tourism and trade of food products. 
However, since the vaccination pro-
gram was started in 1998, disease inci-
dence has decreased. During the study 
period, no other alternative prevention 
measures that could have had an effect 
on disease control were implemented.
High levels of vaccination cover-
age have not been achieved since the 
start of the campaign, and no catch-up 
vaccination program has been imple-
mented. The decrease in hepatitis A 
incidence we observed involved all 
age groups, including those not cov-
ered by the vaccination program. This 
ﬁ  nding may indicate strong herd im-
munity, which would conﬁ  rm  what 
has been observed in other countries 
(7–9). However, there is uncertainty 
in interpreting current epidemiologic 
data. On the basis of available data, 
we cannot assess whether the current 
low incidence of hepatitis A in Pug-
lia is caused by vaccination alone or 
in combination with other factors. We 
also cannot exclude the possibility that 
what we observed may have been an 
interepidemic period and that new epi-
sodes may occur in the future.
Our results indicate that local 
health authorities should be aware of 
possible increases in the incidence of 
hepatitis A in Puglia. An urgent catch-
up vaccination program may be nec-
essary to prevent future outbreaks. 
Moreover, a seroepidemiologic survey 
would be useful for assessing the size 
of the susceptible population and most 
vulnerable age groups.
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Figure. Incidence of hepatitis A in Puglia, Italy (gray line) compared with the rest of Italy 
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Human 
Rickettsia sibirica 
mongolitimonae 
Infection, Spain
To the Editor: Rickettsia sibirica 
mongolitimonae has been recently re-
ported as a subspecies of R. sibirica 
(1). The ﬁ  rst evidence of R. sibirica 
mongolitimonae pathogenicity in hu-
mans was documented in France in 
1996 (2). Since then, 11 more cases in 
France, Algeria, South Africa, Greece, 
and Portugal have been reported (3–
6). Because the main clinical mani-
festations include lymphangitis, the 
acronym LAR (lymphangitis-associ-
ated rickettsiosis) has been proposed 
(3). We report a case from Spain that 
conﬁ  rms the broad distribution of this 
agent in southern Europe.
A 41-year-old man was admitted 
on June 19, 2007, to the Hospital de 
Cruces (Baracaldo, Spain) with fever 
(39°C), malaise for a week, sweating, 
lumbar and knee pain, disseminated 
myalgias, and headache. He reported 
that 20 days before admission he had 
removed an engorged tick from his 
right leg while working as a topogra-
pher in the Balmaseda Mountains, 30 
km from Bilbao. He had also removed 
several ticks from his body 4 days be-
fore the onset of symptoms. Physical 
examination did not demonstrate rel-
evant ﬁ  ndings. There was no inocula-
tion eschar at the tick-bite sites. Rash, 
lymphadenopathies, and lymphangitis 
were not observed.
Chest radiograph did not show 
consolidation or other abnormal-
ity. Initial laboratory examination, 
on June 21, 2007, showed a leuko-
cyte count 5.2 × 103/μL, hemoglobin 
14.1 g/dL, platelet count 190,000/μL, 
erythrocyte sedimentation speed 9 
mm/h, urea 38 mg/dL, creatinine 0.9 
mg/dL, aspartate aminotransferase 
229 IU/L, alanine aminotransferase 
170 IU/L, alkaline phosphatase 158 
IU/L, gamma-glutamyl-transpeptidase 
111 IU/L, total bilirubin 1.3 mg/dL, 
and C-reactive protein 4.3 mg/dL. Be-
cause the patient had been bitten by a 
tick, acute-phase serum and EDTA-
treated blood samples were sent to the 
Special Pathogens Laboratory (Área 
de Enfermedades Infecciosas – Hospi-
tal San Pedro from La Rioja), where a 
presumptive diagnosis of rickettsiosis 
was made. On June 22, 2007, treat-
ment with doxycycline was begun 
(100 mg/day for 12 days), and his con-
dition rapidly improved.
The early-phase serum yielded 
low immunoglobulin (Ig) G titer 
(<64) against Rickettsia conorii and 
Anaplasma phagocytophilum anti-
gens, and results of ELISA and West-
ern blotting for Lyme borreliosis were 
negative. A convalescent-phase serum 
sample collected 7 weeks later did not 
contain IgG antibodies against spotted 
fever group Rickettsia species when R. 
conorii antigen was used.
DNA was extracted from the 
early whole-blood specimen by using 
QIAamp DNA Blood minikit (QIA-
GEN, Hilden, Germany) according to 
the manufacturer’s instructions. This 
DNA extract was used as template 
in nested PCR assays targeting the 
spotted fever group rickettsial ompB 
(420 bp) and gltA (337 bp) genes (7). 
Quality control included both positive 
(with R. conorii Malish #7 grown in 
Vero cells) and negative controls that 
were extracted and PCR ampliﬁ  ed in 
parallel with the specimens. Negative 
controls consisted of sterile water in-
stead of template DNA. Ampliﬁ  cation 
products of the expected size were 
obtained. The sequences of these am-
plicons allowed the identiﬁ  cation of R. 
sibirica mongolitimonae with 99.5% 
and 100% similarity for ompB and 
gltA, respectively (GenBank accession 
nos. DQ097083 and DQ097081).
To our knowledge, Rickettsia spe-
cies have never been detected in ticks 
or human specimens in Spain. The host 
ticks of this rickettsia are likely Hya-
lomma species, which are more preva-
lent in southern Spain. In our region 
in northern Spain, Hyalomma mar-
ginatum represented 8% of ticks that 
fed on humans during 2001–2005, al-
though an increase in this number was 
recorded last year (data not shown).
In our patient, Rickettsia’s patho-
genic role was demonstrated by PCR, a 
technique that has previously enabled 
us to identify other arthropod-borne 
Rickettsia species (8,9). This case 
suggests that R. sibirica mongoliti-
monae infection should be considered 
in the differential diagnosis of rick-
ettsiosis and tick-bite febrile patients 
in Spain and conﬁ  rms the distribution 
of this rickettsia in southern Europe. 
According to the literature (3), some 
patients in whom R. sibirica mongoli-
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